Global Biopharmaceutical and Biomedicine Market: Key Developments
In June 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and PT Etana Biotechnologies Indonesia, an Indonesia-based biotechnology company, jointly announced that the Indonesian Food and Drugs Authority (Badan Pengawas Obat dan Makanan) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti- vascular endothelial growth factor (anti-VEGF) monoclonal antibody drug, for five indications including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer(NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer(CC).
In May 2022, JSR Life Sciences, a company offering research products and services for outsourced drug discovery and development, announced the launch of a new business division, Similis Bio, which would function as a partnering division to work with biopharmaceutical companies to improve efficiency and reduce costs related to biosimilar development.
Biopharmaceutical and Biomedicine Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients